Tuberous sclerosis complex, often shortened to TSC, is a genetic condition in which noncancerous growths can develop in many parts of the body, including the brain, skin, kidneys, heart, and lungs. The name comes from the firm, tuber-like growths that can form in the brain. TSC is present from birth, though its features often become noticeable gradually, and the pattern and severity of symptoms differ a great deal from one person to the next.
Some people with TSC have only mild skin findings and no noticeable developmental impact. Others have seizures beginning in infancy along with developmental delay and growths affecting several organs. This range is one of the defining features of the condition, and it means two people with the same gene change can have very different day-to-day experiences.
The genetic basis of TSC
TSC is caused by a variant in one of two genes, TSC1 or TSC2. These genes normally produce proteins called hamartin and tuberin, which work together inside cells to hold back cell growth and division. When a variant disrupts this braking function, cells in certain tissues can multiply and grow in ways they normally would not, forming the benign tumors seen in TSC.
TSC follows an autosomal dominant inheritance pattern, which means a change in just one copy of TSC1 or TSC2 is enough to cause the condition. In practice, about two out of three people with TSC have it as a de novo variant, meaning the gene change arose for the first time in them rather than being inherited from a parent. The remaining cases are inherited from a parent who carries the variant, sometimes with no prior family history recognized because the parent's own features were mild. Variants in TSC1 are somewhat more common in families with more than one affected member, while TSC2 variants are seen more often in de novo cases.
A condition that affects many organs
What sets TSC apart from many single-organ genetic conditions is its reach across body systems. In the brain, growths called cortical tubers and related changes can contribute to seizures, learning differences, and behavioral features. In the skin, patches of lighter pigmentation, small facial growths called angiofibromas, and thickened patches of skin are common and are often among the earliest visible signs. In the kidneys, benign growths called angiomyolipomas can develop and, if they grow large, may need monitoring or treatment. The heart can be affected before birth or in early infancy by small benign growths that typically shrink over time on their own. In the lungs, some women and people assigned female at birth develop a separate but related lung condition later in life. Because no two organ systems are affected the same way in every person, care teams typically screen each system on its own schedule rather than assuming one area predicts another.
Seizures and epilepsy in TSC
Seizures are one of the most common features of TSC and, for many families, one of the first signs that prompts an evaluation. Seizure types vary widely and can include infantile spasms in babies, seizures that affect awareness or behavior without obvious convulsions, and more typical convulsive seizures. Seizures can begin at any age, though many start in the first year or two of life.
Because seizures in TSC can be frequent, varied, or resistant to standard medications, ongoing seizure and neurological management is typically coordinated with a neurologist rather than handled through periodic check-ins alone. This usually means regular visits to track seizure patterns, adjust medication as needed, and watch for related effects on development, attention, and behavior. Families often find that this neurology relationship becomes one of the more consistent threads in an otherwise multidisciplinary care plan.
Managing TSC
There is no cure for TSC, so management focuses on monitoring each affected organ and treating complications as they arise. Seizures are usually addressed first with anti-seizure medications, and a few medications developed specifically with TSC in mind are now used for seizures that do not respond well to standard options. Growths in the kidneys and brain are typically followed with periodic imaging, and treatment, including surgery or medications that target the same cell-growth pathway disrupted by TSC1 and TSC2, is reserved for growths that are changing or causing symptoms. Skin findings are sometimes treated for cosmetic reasons but rarely require urgent care. Developmental and behavioral support, including therapy for learning, communication, or social differences, is often built into the care plan from an early age rather than added only if problems appear later.
Genetic counseling is a useful step for families, both to confirm the diagnosis through testing and to understand recurrence risk for future children. This information is educational and not a substitute for a clinical evaluation. A diagnosis of TSC, or a question about symptoms that might point toward it, is best worked through with a genetic counselor or physician who can review the full clinical picture.